495 related articles for article (PubMed ID: 21367748)
1. Aberrations of EZH2 in cancer.
Chase A; Cross NC
Clin Cancer Res; 2011 May; 17(9):2613-8. PubMed ID: 21367748
[TBL] [Abstract][Full Text] [Related]
2. (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells.
Choudhury SR; Balasubramanian S; Chew YC; Han B; Marquez VE; Eckert RL
Carcinogenesis; 2011 Oct; 32(10):1525-32. PubMed ID: 21798853
[TBL] [Abstract][Full Text] [Related]
3. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.
Varambally S; Cao Q; Mani RS; Shankar S; Wang X; Ateeq B; Laxman B; Cao X; Jing X; Ramnarayanan K; Brenner JC; Yu J; Kim JH; Han B; Tan P; Kumar-Sinha C; Lonigro RJ; Palanisamy N; Maher CA; Chinnaiyan AM
Science; 2008 Dec; 322(5908):1695-9. PubMed ID: 19008416
[TBL] [Abstract][Full Text] [Related]
4. PRC2-independent chromatin compaction and transcriptional repression in cancer.
Vallot C; Hérault A; Boyle S; Bickmore WA; Radvanyi F
Oncogene; 2015 Feb; 34(6):741-51. PubMed ID: 24469045
[TBL] [Abstract][Full Text] [Related]
5. Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (EZH2).
Xu X; Chen J; Wang G; Zhang X; Li Q; Zhou X; Guo F; Li M
Bioorg Med Chem Lett; 2024 Jan; 97():129558. PubMed ID: 37956762
[TBL] [Abstract][Full Text] [Related]
6. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.
Bracken AP; Pasini D; Capra M; Prosperini E; Colli E; Helin K
EMBO J; 2003 Oct; 22(20):5323-35. PubMed ID: 14532106
[TBL] [Abstract][Full Text] [Related]
7. EZH2 expression is associated with inferior overall survival in mantle cell lymphoma.
Martinez-Baquero D; Sakhdari A; Mo H; Kim DH; Kanagal-Shamanna R; Li S; Young KH; O'Malley DP; Dogan A; Jain P; Wang ML; McDonnell TJ; Miranda RN; Vega F; Medeiros LJ; Ok CY
Mod Pathol; 2021 Dec; 34(12):2183-2191. PubMed ID: 34376807
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation.
Momparler RL; Côté S; Momparler LF; Idaghdour Y
Clin Epigenetics; 2014; 6(1):19. PubMed ID: 25313314
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of Enhancer of Zeste Homolog 2 (EZH2) with Associated pERK Co-Expression and PRC2 Complex Protein SUZ12 Correlation in Adult T-Cell Leukemia/Lymphoma.
Chai J; Choudhuri J; Gong JZ; Wang Y; Tian X
Cancers (Basel); 2024 Feb; 16(3):. PubMed ID: 38339397
[TBL] [Abstract][Full Text] [Related]
10. Polycomb Directed Cell Fate Decisions in Development and Cancer.
German B; Ellis L
Epigenomes; 2022 Sep; 6(3):. PubMed ID: 36135315
[TBL] [Abstract][Full Text] [Related]
11. An overview of the development of EED inhibitors to disable the PRC2 function.
Liu KL; Zhu K; Zhang H
RSC Med Chem; 2022 Jan; 13(1):39-53. PubMed ID: 35224495
[TBL] [Abstract][Full Text] [Related]
12. EED related overgrowth: First report of multiple members in a single family.
Goel H; O'Donnell S; Edwards M
Am J Med Genet A; 2024 Feb; 194(2):374-382. PubMed ID: 37840385
[TBL] [Abstract][Full Text] [Related]
13. Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer.
Ghamlouch H; Boyle EM; Blaney P; Wang Y; Choi J; Williams L; Bauer M; Auclair D; Bruno B; Walker BA; Davies FE; Morgan GJ
J Exp Clin Cancer Res; 2021 Dec; 40(1):380. PubMed ID: 34857028
[TBL] [Abstract][Full Text] [Related]
14. EZH2: The roles in targeted therapy and mechanisms of resistance in breast cancer.
Chen Y; Zhu H; Luo Y; Tong S; Liu Y
Biomed Pharmacother; 2024 Apr; 175():116624. PubMed ID: 38670045
[TBL] [Abstract][Full Text] [Related]
15. AI-driven designed protein epigenomics.
Levy S; Ruohola-Baker H
Clin Res Oncol; 2023; 1(1):1-3. PubMed ID: 38037660
[TBL] [Abstract][Full Text] [Related]
16. Retraction for Berthier et al., PINK1 regulates histone H3 trimethylation and gene expression by interaction with the polycomb protein EED/WAIT1.
Proc Natl Acad Sci U S A; 2014 Nov; 111(45):16225. PubMed ID: 25331905
[No Abstract] [Full Text] [Related]
17. Author Correction: An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.
Souroullas GP; Jeck WR; Parker JS; Simon JM; Liu JY; Paulk J; Xiong J; Clark KS; Fedoriw Y; Qi J; Burd CE; Bradner JE; Sharpless NE
Nat Med; 2024 Feb; ():. PubMed ID: 38383796
[No Abstract] [Full Text] [Related]
18. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
[TBL] [Abstract][Full Text] [Related]
19. EZH2 methyltransferase and H3K27 methylation in breast cancer.
Yoo KH; Hennighausen L
Int J Biol Sci; 2012; 8(1):59-65. PubMed ID: 22211105
[TBL] [Abstract][Full Text] [Related]
20. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
Xu B; Konze KD; Jin J; Wang GG
Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
